Alternate Name(s):
PROFASI HP
Classification:
Hormonal agent- Gonadotropin - NON-CYTOTOXIC HAZARDOUS
Original Date:
August 2005
Revised Date:
June 2015
Indications:
- Gonadotropin for various male and female hormone deficiencies
- Prepubertal cryptochidism
- Hypogonadotropic hypogonadism
- Habitual abortion
- Functional sterility in females
Reconstitution and Stability:
- Unreconstituted vial stored at room temperature
- Stable in fridge for 30 days after reconstitution
- Reconstitute with 10 mL diluent provided by the manufacturer
Compatibility:
- Solutions Compatible: diluent provided by the manufacturer
- Additives/Above Cassette Compatible: no information
- Y-site Compatible: no information
- Incompatible: DO NOT mix with other drugs
Administration:
(For approved routes of administration by nursing personnel, refer to Policy for the Administration of Intravenous Medications.)
| SC | NO |
| IM | YES |
| IV Push |
NO |
| IV Intermittant Infusion |
NO |
| IV Continuous Infusion | NO |
Dosage:
(For neonatal dosages, refer to Neonatal IV Drug Manual.)
IM ONLY:
- Individualized: See product monograph (there are many variations of the dosage regimen)
- Prepubertal cryptochidism: 1000-5000 units 2-3 times/week for 3 weeks or
5000 units every 2nd day for 4 injections or
1000-2000 units/m2/dose 3 times/week for 3 weeks - Hypogonadotropic hypogonadism: 500-1000 units 3 times/week for 3 weeks, followed by the same dose twice weekly for 3 weeks
Potential hazards of parenteral administration:
- Pain at injection site
- Headache, irritability, depression, fatigue, edema, precocious puberty, gynecomastia, premature closure of epiphyses
Notes:
- Discontinue if vaginal bleeding occurs
- Treatment for cryptochidism may produce precocious puberty; may be indication to discontinue treatment
- Contraindicated in androgenic neoplasms
- May cause fluid retention- use with caution in cardiac diseases, migraine or epilepsy